Original-Research: Epigenomics AG – von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Epigenomics AG Unternehmen: Epigenomics AG ISIN: DE000A11QW50 Anlass der Studie: Update Empfehlung: BUY seit: 06.10.2017 Kursziel: €7,30 Kursziel auf Sicht von: 12 Monaten Letzte Ratingänderung: 06.10.2017; vormals Add Analyst: Simon Scholes, CFA First Berlin Equity Research has […]
Year: 2017
06. October 2017
Original-Research: Epigenomics AG (von First Berlin Equity Research GmbH)
Read more
20. September 2017
Epigenomics AG issues new shares by way of private placement
Epigenomics AG / Key word(s): Capital Increase 20-Sep-2017 / 21:18 CET/CESTDisclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP – a service of EQS Group AG.The issuer is solely responsible for the content of this announcement. Publication of Inside Information according to Article 17 MAR Epigenomics AG issues new shares by […]
08. September 2017
Epigenomics AG issues convertible bonds
DGAP-News: Epigenomics AG / Key word(s): Corporate Action 08.09.2017 / 08:55 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG issues convertible bonds Berlin (Germany) and Germantown, MD (U.S.A.), September 8, 2017 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY), or the “Company”, today announced that it has issued convertible […]
30. August 2017
Epigenomics Commences Post Approval Study on Epi proColon(R)
DGAP-News: Epigenomics AG / Key word(s): Study 30.08.2017 / 11:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics Commences Post Approval Study on Epi proColon(R) Berlin (Germany) and Germantown, MD (U.S.A.), August 30, 2017 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), today announced the initiation of a […]
23. August 2017
Epigenomics AG: Veröffentlichung gemäß § 26 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
Epigenomics AG 23.08.2017 / 15:37 Veröffentlichung einer Stimmrechtsmitteilung übermittelt durch DGAP – ein Service der EQS Group AG.Für den Inhalt der Mitteilung ist der Emittent verantwortlich. Stimmrechtsmitteilung 1. Angaben zum Emittenten Epigenomics AG Geneststraße 5 10829 Berlin Deutschland 2. Grund der Mitteilung X Erwerb/Veräußerung von Aktien mit Stimmrechten Erwerb/Veräußerung von Instrumenten Änderung der […]
09. August 2017
Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results
DGAP-News: Epigenomics AG / Key word(s): Half Year Results 09.08.2017 / 08:45 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Announces 2017 Second Quarter and Six Months Financial Results – Reimbursement in the United States is a focus of the company as it will have the greatest impact […]